Effects of neoadjuvant chemotherapy for patients with obstructive colon cancer: A multicenter propensity score‐matched analysis (YCOG2101)
Abstract Aim Obstructive colon cancer is locally advanced colon cancer with poor prognosis. However, the effect of neoadjuvant chemotherapy (NAC) on obstructive colon cancer remains unclear. Therefore, this study aimed to investigate the safety and efficacy of NAC in patients with obstructive colon...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-03-01
|
| Series: | Annals of Gastroenterological Surgery |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ags3.12736 |
| _version_ | 1797272598065709056 |
|---|---|
| author | Kazuya Nakagawa Atsushi Ishibe Hiroki Ohya Mayumi Ozawa Yusuke Suwa Jun Watanabe Hirokazu Suwa Kanechika Den Koichi Mori Masashi Momiyama Koki Goto Itaru Endo |
| author_facet | Kazuya Nakagawa Atsushi Ishibe Hiroki Ohya Mayumi Ozawa Yusuke Suwa Jun Watanabe Hirokazu Suwa Kanechika Den Koichi Mori Masashi Momiyama Koki Goto Itaru Endo |
| author_sort | Kazuya Nakagawa |
| collection | DOAJ |
| description | Abstract Aim Obstructive colon cancer is locally advanced colon cancer with poor prognosis. However, the effect of neoadjuvant chemotherapy (NAC) on obstructive colon cancer remains unclear. Therefore, this study aimed to investigate the safety and efficacy of NAC in patients with obstructive colon cancer. Methods From January 2012 to December 2017, we collected patient data for clinical stage II/III obstructive colon cancer at seven Yokohama Clinical Oncology Group (YCOG) institutions. The long‐term outcomes of the NAC and non‐NAC groups were analyzed retrospectively after adjusting for patients' background characteristics using propensity score matching. Results Among the 202 eligible patients, propensity score matching extracted 51 patients each for the NAC and non‐NAC groups. After matching, the groups showed no marked differences in the background factors. All the patients in the NAC group underwent diverting stoma construction. Nineteen patients (37.3%) experienced grade 3–4 adverse events during NAC. The incidence of postoperative complications was similar between groups. The 5‐year progression‐free survival rates were 75.8% in the NAC group and 63.0% in the non‐NAC group (p = 0.22, log‐rank test). The 5‐year overall survival rates were 88.5% in the NAC group and 78.8% in the non‐NAC group (p = 0.09, log‐rank test). Conclusion Although NAC was feasible for obstructive colon cancer after diverting stoma construction, its effects on long‐term outcomes could not be proven. |
| first_indexed | 2024-03-07T14:31:39Z |
| format | Article |
| id | doaj.art-1522b0a39d25446a8769ce2d79e4fd11 |
| institution | Directory Open Access Journal |
| issn | 2475-0328 |
| language | English |
| last_indexed | 2024-03-07T14:31:39Z |
| publishDate | 2024-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | Annals of Gastroenterological Surgery |
| spelling | doaj.art-1522b0a39d25446a8769ce2d79e4fd112024-03-06T03:47:05ZengWileyAnnals of Gastroenterological Surgery2475-03282024-03-018226227210.1002/ags3.12736Effects of neoadjuvant chemotherapy for patients with obstructive colon cancer: A multicenter propensity score‐matched analysis (YCOG2101)Kazuya Nakagawa0Atsushi Ishibe1Hiroki Ohya2Mayumi Ozawa3Yusuke Suwa4Jun Watanabe5Hirokazu Suwa6Kanechika Den7Koichi Mori8Masashi Momiyama9Koki Goto10Itaru Endo11Department of Gastroenterological Surgery Yokohama City University Graduate School of Medicine Yokohama JapanDepartment of Gastroenterological Surgery Yokohama City University Graduate School of Medicine Yokohama JapanDepartment of Gastroenterological Surgery Yokohama City University Graduate School of Medicine Yokohama JapanDepartment of Gastroenterological Surgery Yokohama City University Graduate School of Medicine Yokohama JapanDepartment of Surgery, Gastroenterological Center Yokohama City University Medical Center Yokohama JapanDepartment of Surgery, Gastroenterological Center Yokohama City University Medical Center Yokohama JapanDepartment of Surgery Yokosuka Kyousai Hospital Yokosuka JapanDepartment of Surgery Yokohama City Minato Red Cross Hospital Yokohama JapanDepartment of Surgery Fujisawa City Hospital Fujisawa JapanDepartment of Surgery NTT Medical Center Tokyo Tokyo JapanDepartment of Surgery Yokohama Medical Center Yokohama JapanDepartment of Gastroenterological Surgery Yokohama City University Graduate School of Medicine Yokohama JapanAbstract Aim Obstructive colon cancer is locally advanced colon cancer with poor prognosis. However, the effect of neoadjuvant chemotherapy (NAC) on obstructive colon cancer remains unclear. Therefore, this study aimed to investigate the safety and efficacy of NAC in patients with obstructive colon cancer. Methods From January 2012 to December 2017, we collected patient data for clinical stage II/III obstructive colon cancer at seven Yokohama Clinical Oncology Group (YCOG) institutions. The long‐term outcomes of the NAC and non‐NAC groups were analyzed retrospectively after adjusting for patients' background characteristics using propensity score matching. Results Among the 202 eligible patients, propensity score matching extracted 51 patients each for the NAC and non‐NAC groups. After matching, the groups showed no marked differences in the background factors. All the patients in the NAC group underwent diverting stoma construction. Nineteen patients (37.3%) experienced grade 3–4 adverse events during NAC. The incidence of postoperative complications was similar between groups. The 5‐year progression‐free survival rates were 75.8% in the NAC group and 63.0% in the non‐NAC group (p = 0.22, log‐rank test). The 5‐year overall survival rates were 88.5% in the NAC group and 78.8% in the non‐NAC group (p = 0.09, log‐rank test). Conclusion Although NAC was feasible for obstructive colon cancer after diverting stoma construction, its effects on long‐term outcomes could not be proven.https://doi.org/10.1002/ags3.12736diverting stomaneoadjuvant chemotherapyobstructive colon cancer |
| spellingShingle | Kazuya Nakagawa Atsushi Ishibe Hiroki Ohya Mayumi Ozawa Yusuke Suwa Jun Watanabe Hirokazu Suwa Kanechika Den Koichi Mori Masashi Momiyama Koki Goto Itaru Endo Effects of neoadjuvant chemotherapy for patients with obstructive colon cancer: A multicenter propensity score‐matched analysis (YCOG2101) Annals of Gastroenterological Surgery diverting stoma neoadjuvant chemotherapy obstructive colon cancer |
| title | Effects of neoadjuvant chemotherapy for patients with obstructive colon cancer: A multicenter propensity score‐matched analysis (YCOG2101) |
| title_full | Effects of neoadjuvant chemotherapy for patients with obstructive colon cancer: A multicenter propensity score‐matched analysis (YCOG2101) |
| title_fullStr | Effects of neoadjuvant chemotherapy for patients with obstructive colon cancer: A multicenter propensity score‐matched analysis (YCOG2101) |
| title_full_unstemmed | Effects of neoadjuvant chemotherapy for patients with obstructive colon cancer: A multicenter propensity score‐matched analysis (YCOG2101) |
| title_short | Effects of neoadjuvant chemotherapy for patients with obstructive colon cancer: A multicenter propensity score‐matched analysis (YCOG2101) |
| title_sort | effects of neoadjuvant chemotherapy for patients with obstructive colon cancer a multicenter propensity score matched analysis ycog2101 |
| topic | diverting stoma neoadjuvant chemotherapy obstructive colon cancer |
| url | https://doi.org/10.1002/ags3.12736 |
| work_keys_str_mv | AT kazuyanakagawa effectsofneoadjuvantchemotherapyforpatientswithobstructivecoloncanceramulticenterpropensityscorematchedanalysisycog2101 AT atsushiishibe effectsofneoadjuvantchemotherapyforpatientswithobstructivecoloncanceramulticenterpropensityscorematchedanalysisycog2101 AT hirokiohya effectsofneoadjuvantchemotherapyforpatientswithobstructivecoloncanceramulticenterpropensityscorematchedanalysisycog2101 AT mayumiozawa effectsofneoadjuvantchemotherapyforpatientswithobstructivecoloncanceramulticenterpropensityscorematchedanalysisycog2101 AT yusukesuwa effectsofneoadjuvantchemotherapyforpatientswithobstructivecoloncanceramulticenterpropensityscorematchedanalysisycog2101 AT junwatanabe effectsofneoadjuvantchemotherapyforpatientswithobstructivecoloncanceramulticenterpropensityscorematchedanalysisycog2101 AT hirokazusuwa effectsofneoadjuvantchemotherapyforpatientswithobstructivecoloncanceramulticenterpropensityscorematchedanalysisycog2101 AT kanechikaden effectsofneoadjuvantchemotherapyforpatientswithobstructivecoloncanceramulticenterpropensityscorematchedanalysisycog2101 AT koichimori effectsofneoadjuvantchemotherapyforpatientswithobstructivecoloncanceramulticenterpropensityscorematchedanalysisycog2101 AT masashimomiyama effectsofneoadjuvantchemotherapyforpatientswithobstructivecoloncanceramulticenterpropensityscorematchedanalysisycog2101 AT kokigoto effectsofneoadjuvantchemotherapyforpatientswithobstructivecoloncanceramulticenterpropensityscorematchedanalysisycog2101 AT itaruendo effectsofneoadjuvantchemotherapyforpatientswithobstructivecoloncanceramulticenterpropensityscorematchedanalysisycog2101 |